St. Anna Kinderkrebsforschung
The Children’s Cancer Research Institute (CCRI) is owned by the private charity-based association St. Anna Kinderkrebsforschung. It was founded in 1988 with the overall aim to improve the treatment options for children suffering from cancer through basic research and translational research. CCRI is closely affiliated with the St. Anna Children’s Hospital, the largest clinical haemato-oncological centre for the treatment of childhood cancer in Austria and its spin-off Labdia Labordiagnostik GmbH. CCRI has formed a comprehensive cancer centre in order to address patient relevant scientific questions to better understand the disease and effective therapies, through bidirectional knowledge exchange from research to clinics and diagnostics.
Thomas Lion is the Project Coordinator, Group Leader at CCRI’s Molecular Microbiology unit and the Medical Director of Labdia. He has over 20 years of experience in R&D and diagnostics in cancer and infectious diseases. He authored more than 150 research articles and book chapters and received 18 national and international awards in recognition of his work. Thomas Lion has been serving for many years as section editor of the journal Leukemia and as a reviewer for other leading scientific journals in his field. He is chairman of the Science and Research Working Party of the Austrian Pediatric Society and previously was coordinator of the FP5 European Concerted Action Eurochimerism Consortium.
Nuno Andrade: International grant manager at CCRI and Labdia. He has extensive experience with administrative and financial handling of FP7 projects and has been involved in numerous European-funded projects both as scientist and manager. He will support the day-to-day management and administration of FUNGITECT.
Sandra Preuner (Researcher/technician)
Filomena Nogueira (Researcher/postdoc)
Stefan Czurda (Researcher/postdoc)
Medizinische Universität Wien
The Medical University of Vienna is the largest medical university research institution in Austria. Founded in 1365 as the Medical Faculty of the University of Vienna, the MUW is now one of the largest medical universities in the world. In 2004, the MUW spun off as an independent Medical University according to the Austrian university act that regulates autonomous self-administration. The MUW research activities range from basic biomedical research to clinical sciences, comprising several main focus areas, including brain research, allergology, infectiology & immunology, oncology, vascular biology, constituting the high international research profile of the MUW, and placing the MUW into the top 100 ranking of medical universities in the world. Moreover, the MUW is involved in world-wide healthcare and hospital management projects in Asia and Middle-East. Finally, the MUW is offering international postgraduate courses for medical doctors and trainees at all experience levels.
Website Kuchler Laboratory: cdl.univie.ac.at
Website Medical University of Vienna: www.meduniwien.ac.at/homepage
Karl Kuchler is a Group Leader at the Department of Medical Biochemistry of the Max F. Perutz Laboratories of the MUW at the Campus Vienna Biocenter (www.mfpl.ac.at/mfpl-group/group/kuchler.html). His team conducts fundamental basic research within FUNGITECT, including the generation of diagnostically relevant tools such as monoclonal antibodies and diagnostic microchips based on fungal-specific monoclonal antibodies. The group will also provide expertise ranging from basic validation of diagnostic assays to the establishment of SOPs. The findings will be translated into the clinical setting in the context of invasive fungal diseases (IFDs). Karl Kuchler will be involved in WP1-WP8 and leading WP2 that focuses on the development of monoclonal antibody arrays for rapid and inexpensive point-of-care fungal diagnosis. His group shall further contribute to optimizing the fungal detection and identification through DNA- and RNA-based methods.
Michael Tscherner (Researcher / Postdoc)
Fabian Istel (Researcher / PhD student)
Florian Zwolanek (Researcher / PhD student)
Saren Tasciyan (Researcher/Diploma student)
Andriy Petryschyn (Research Technician)
Ralica Nikolova (Research Technician)
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V.
Executing Institute: Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Fraunhofer IGB
The Fraunhofer-Gesellschaft is a German research organization founded in 1949. Its research activities are conducted by 67 institutes and independant research units, each focusing on different fields of applied science. Fraunhofer is the largest application-oriented research organization in Europe, and is well known for developing products and processes up to commercial maturity.
The Fraunhofer IGB develops and optimizes processes and products in the fields of medicine, pharmacy, chemistry, the environment and energy. The Fraunhofer IGB has been granted manufacturing authorisations for several healthcare products and offers manufacturing capacity in compliance with GMP guidelines. It has at its disposal modern laboratories equipped with the latest technology.
Steffen Rupp is the Head of Department of Molecular Biotechnology at Fraunhofer IGB and his team will offer key expertise with MALDI-TOF mass spectrometry, NGS technology including data processing for identification of specific pathogen expression signatures, and antibody arrays with the aim of developing a new generation of diagnostic tools. His team will make use of technology to monitor the entire fungal genome and molecular switches that regulate resistance and pathogenicity and will implement in-house skin models to simulate fungal infections and validate the technologies to be developed. The team will be involved in WP1-WP8 and will lead WP3 and WP7.
Kai Sohn: Group leader of Functional Genomics and Leader of WP3. Kai Sohn has extensive expertise in next-generation sequencing for genomics and transcriptomics from sample preparation to bioinformatics to identify and validate biomarkers for major diseases including fungal infections and to develop novel diagnostic tools.
Ekkehard Hiller: Lab scientist
Gabriele Zelt: Technician
Javna Ustanova Univerzitet U Tuzli Universitas Studiorum Tuzlaensis
Country: Bosnia and Herzegovina
The University of Tuzla (UNTZ) was established in 1976 and it was the first integrated university in Bosnia and Herzegovina. The University currently has 12 faculties and one academy (Academy of Performing Arts) with broad research interest in technical, applied and biomedical sciences. The University has participated in a number of research and developmental projects in all fields of studies taught and researched at the University, at both national and international levels. With over 50 cooperation agreements with universities worldwide, the University invests its outmost efforts to strengthen the ties with national and international academic community and strengthen the process of internationalization.
Nadira Ibrišimović Mehmedinović is an Assistant Professor of Inorganic Chemistry at the University of Tuzla and guest lecturer at the University of Vienna. Her research areas involve protein chemistry, development of optical biosensor technologies and their application in the surveillance of microbiological contaminations. NadiraIbrišimović has been the key person and the main innovator in development and optimisation of various biomimetic sensor-setups for real-time monitoring of lytic enzyme activity in microorganisms.
Mirza Ibrišimović is research scientist working on the FUNGITECT project at the University of Tuzla. Mirza Ibrišimović has PhD in Molecular Biology and his field of research includes biochemistry, biotechnology (development of biosensor chips), cell biology, molecular genetics, microbiology and virology. He has also been one of the main innovators of the patented sensor setup for real-time monitoring of microbial enzymes.
Aldina Kesić: Researcher
Jasmina Dedić: Master student
Genedata transforms data into intelligence with a portfolio of advanced software solutions and scientific consulting services. These solutions and services are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
Thomas Hartsch joined Genedata for more than nine years ago. At Genedata he oversees the business development, market segmentation, product commercialisation and consulting project management of the Genedata Selector Solutions in Europe.
Sebastien Ribrioux has several years of experience in software development and project management for bio-marker discovery in pharmaceutical R&D. At Genedata, he is in charge for professional services management, supervision of projects including scientific consulting and training.
Ludwig Macko is the Head of Software Engineering and has been the main innovator from the first days of Genedata in developing and combining data processing pipelines for genomes with scalable relational database solutions coupled with analysis tools to provide an integrative view of complex data.
Molzym GmbH & Co KG
Molzym is a biotech company committed to innovative solutions for biological research and diagnosis of infectious diseases. Molzym’s developmental efforts are particularly focused on new processes enabling and facilitating the molecular diagnosis of diseases caused by bacteria and fungi. Among the key technologies is MolYsis™ which is a process for the targeted isolation of pathogen DNA from a variety of clinical samples. Manual and automated pathogen testing devices are available for IVD. The portfolio of research articles comprises of DNA-free reagents like highly active Taq polymerase and master mixes for Real-Time PCR analysis. Molzym’s products are sold worldwide via a network of distributors.
Website: www.molzym.com and www.sepsitest.com
Michael Lorenz holds a PhD and habilitation degree for microbial genetics and is co-founder and CEO of Molzym. He has extensive industrial experience in molecular diagnostics and has been responsible for launching several diagnostic products and platforms on the market. Michael Lorenz has been the key person in developing Molzym’s proprietary MolYsis™ technology.
Claudia Disqué: Molzym’s technological project manager with responsibility of experimental design for new developments. Claudia Disqué holds a PhD degree in molecular biology and has many years of experience in R&D for molecular diagnostics. She is currently involved in several R&D activities at Molzym.
Sonja Keim: Master in biotechnological engineering and has a long year experience in experimentation in the field of molecular diagnostics. She will be involved in the experimental performance of WPs.